Colorectal cancer (CRC), which comprises colon and/or rectum cancer, represents a significant health problem as the world’s third most diagnosed and second fatal cancer globally. Approximately 9.4% of cancer-related deaths were due to CRC in 2020. Biomarkers for detecting CRC must allow detection of the disease at earlier stages. Such tests using biomarkers should have high sensitivity and specificity to prevent subjecting healthy individuals to unnecessary colonoscopies. Carcinoembryonic antigen (CEA) has been the most extensively investigated tumor marker for colon cancer. CEA is present in normal adult tissues in addition to malignant tissues, but very low levels normally are seen in the blood from healthy individuals with normal concentrations of 2.5 to 5.0 ng/ml. Although 80% or more of patients with advanced colonic adenocarcinoma have circulating CEA, the CEA assay should not be used as the sole diagnostic test for suspected carcinoma. The combined assays of CEA and Carbohydrate antigen 19-9 (CA 19.9) may increase diagnostic sensitivity in colorectal cancer detection. Moreover, the determination of both markers is used as a postoperative prognostic factor in the evaluation of the stage of the disease and survival rate. A high level of tissue polypeptide specific antigen (TPS) occurs in about 60–80% of patients with colorectal cancer. Serum concentrations of Tumor-associated glycoprotein-72 (TAG-72) were elevated in 43% of patients with colorectal cancer. It is advisable to determine TAG-72 together with other markers, primarily CEA. Sixty-one percent of patients had at least one marker with elevated levels when measuring these three markers. Other studies showed elevated levels of several proinflammatory cytokines, such as interleukin-6 (IL 6), IL 8, tumor necrosis factor-α (TNF-α) and acute-phase proteins in patients with colorectal carcinoma and other malignancies. Mroczko et al showed a potential role for stem cell factor and IL 3 as tumor markers for colorectal cancer, especially in combination with CEA and CA19-9.